Business Wire

MIRIS

30.9.2020 07:02:12 CEST | Business Wire | Press release

Share
Aurora Sustainability: Changing the World With the Network Effect

«Be the change you want to see in the world, » is a well-worn cliché. However, most of us feel overwhelmed in the face of the climate and environmental challenges. Instead of giving in, Cape Town-based Danielle Laity and her team decided to do something. They’ve started a new community: Aurora Sustainability .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005910/en/

“In Cape Town, we feel the need for a more sustainable and fairer world every day. Food security is an issue, the predominantly fossil fuel based electrical grid is under strain and climate change will only exacerbate these problems” says Danielle Laity.

On the Aurora community platform, anyone can log on and take a quick quiz that tells you the size of your carbon footprint. The intention is not to compete or compare yourself to others; it’s to get a measure of how sustainable you are today, and then receive the information and inspiration needed to make sustainable lifestyle changes.

An overwhelming problem

An ocean filled with plastic, carbon emissions out of control despite major international agreements, and every year the world's population increases by about 1 percent; approximately 80 million people.

In South Africa these problems are felt even more precariously than if, for example, one lives in Norway where the effects may not be seen in day to day life.

The climate crisis has been created by the sum of all human action, so if each of us does something, we can contribute a little to solving the problem.

Aurora Sustainability is now beta testing its second version, and they have already gained over 10,000 users. It was launched in South Africa, but they are now rolling it out in Norway as their second country.

“Where one individual may seem powerless, 10,000 people who take action is starting to look like a movement, and we are only getting started,” says Laity.

Aurora Sustainability will use the network effect to change the world

When a network effect is present, the value of a product increases according to the number of others using it. Our users will be able to tell each other about changes they have made, and point each other towards greener choices.

“It’s possible for consumers to drive industry if we come together to make a difference,” says Laity.

When you take the quiz, you get an Aurora score divided into five areas. The higher the score, the more sustainable you are. The five areas measured are energy use, transport, food, other consumption and investments. If, for example, you start cycling to work, then you will be able to see what change this makes to your CO2 footprint.

In your dashboard you will have a complete overview of how sustainable your lifestyle is (or not). For many, it does not make much sense to talk about kilograms of CO2 saved, therefore Aurora also makes comparisons to units that are more specific. For example, how many loads of washing you have saved.

Her ambitions for Aurora Sustainability are grand: “We will be the community for everyone who wants to make a difference. Those who don’t want to wait for politicians to make all the choices, but who make concrete choices in their everyday lives. There are enough people to be able to make a big difference here and now,” says Laity.

Aurora community is a Miris initiative; the disruptive, greentech, real estate company.

Join the Aurora community on Facebook, Instagram South Africa and Instagram Norway , and take the quiz here .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye